Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xilonix in Pyoderma Gangrenosum
NCT01965613Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bermekimab in pyoderma gangrenosum (PG), sponsored by Janssen Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
bermekimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT01965613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965613.